Search CommunityWalk:


Symphony Evolution, Inc

7361 Calhoun Place
Rockville, MD 20855, USA

Category: Pharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Symphony Evolution, Inc is a biopharmaceutical company focused on the development of therapeutics for treating cancer and diabetic neuropathy. The company was founded in 2002 by Harri V. Taranto.

Symphony Evolution's product portfolio includes: XL647, a potent inhibitor of RTKs (receptor tyrosine kinases) implicated in driving tumor proliferation and vascularization; XL999, a potent inhibitor of Flt3 indicated as an important driver of cell proliferation in many patients with acute myelogenous leukemia (AML); and XL784, a potent inhibitor of the ADAM-10 metalloprotease (MP) enzyme indicated for the treatment of renal disease.

Symphony Evolution has a collaboration with Exelixis, Inc. The company's lead investor is Symphony Capital Partners, L.P.